Cingulate Inc. (CING) Stock Score, Valuation & Financial Research

Cingulate Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CING

Cingulate Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.89. These figures are a research snapshot, not a buy or sell recommendation.

What Cingulate Inc. does

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cingulate is a clinical-stage biopharmaceutical company that utilizes its proprietary Precision Timed Release (PTR) drug delivery platform to develop pharmaceutical candidates. The company intends to generate future revenue by commercializing these products, primarily through strategic partnerships, licensing agreements, and multi-channel marketing strategies targeting physicians and patients.

Products and services

  • The company is developing a pipeline of drug candidates including CTx-1301, CTx-1302, and CTx-2103, which are designed to provide three distinct releases of active pharmaceutical ingredients to improve treatment regimens for conditions such as ADHD and anxiety.

Brands and product families

  • CTx-1301 — Lead ADHD drug candidate utilizing the PTR platform. Source
  • CTx-1302 — ADHD drug candidate utilizing the PTR platform. Source
  • CTx-2103 — Anxiety drug candidate utilizing the PTR platform. Source

Customer types

Physicians; Payers; Patients and patient caregivers.

Suppliers, materials and equipment

  • Societal CDMO, Inc. (doing business as Bend Biosciences) — Contract development and manufacturing organization responsible for manufacturing clinical, registration, and commercial batches of the lead ADHD candidate, CTx-1301. Source

Business strengths to evaluate

  • Proprietary Precision Timed Release (PTR) drug delivery platform technology Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on third-party contract manufacturing organizations for product production Source

Sources: Company research source · CTx-1301 · Proprietary Precision Timed Release (PTR) drug delivery platform technology · History of operating losses and accumulated deficit

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CING financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.89
Market capitalization:
65.86M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -28.8M
Free cash flow:
USD -17.41M
Cash:
USD 28.4M
Total debt:
USD 6.29M
EPS:
USD -5.01

What stands out

  • Free cash flow is USD -17.41M, negative for the stored period.
  • The balance sheet shows USD 28.4M of cash versus USD 6.29M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 22.11M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CING

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CING fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CING likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CING to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CING's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CING

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.